Denmark, through the Danish Medicines Council, will join FINOSE! We at Quantify foresee that this can potentially be a great preparation for both HTA bodies and pharmaceutical manufacturers for the upcoming EU HTA regulation. The addition of Denmark to FINOSE will likely also make the FINOSE pathway more attractive for pharmaceutical companies, when considering their HTA and market access options in the Nordics. Quantify, with our vast experience in Nordic HTA submissions, would be happy to partner with you or give strategic advice for potential FINOSE processes.
However, the million dollar question remains – will FINOSE change its name? Share your best ideas on a new name in the comments! 🙌